CytomX Therapeutics: Varseta-M Phase 1 expansion data Q1 2026, initial data by 1H 2027.
ByAinvest
Thursday, Jan 8, 2026 8:14 am ET1min read
CTMX--
CytomX Therapeutics announced a business update and anticipated milestones for 2026. The company expects CX-2051 expansion data for colorectal cancer in Q1 2026, while the Varsetatug masetecan Phase 1 combination study with bevacizumab will start in Q1 2026 with initial data expected by 1H 2027. Initial CX-801 Masked Interferon-alpha-2b Phase 1 combination data with KEYTRUDA in melanoma is expected by the end of 2026. CytomX will present at the 44th Annual JP Morgan Healthcare Conference on January 14th.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet